Get the Stockscreener App
10.56
6.56%
0.65
After Hours:
10.75
0.19
+1.80%
Bioventus Inc stock is traded at $10.56, with a volume of 831.51K.
It is up +6.56% in the last 24 hours and up +22.51% over the past month.
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
See More
Previous Close:
$9.91
Open:
$10.21
24h Volume:
831.51K
Relative Volume:
2.33
Market Cap:
$711.41M
Revenue:
$568.09M
Net Income/Loss:
$27.27M
P/E Ratio:
32.23
EPS:
0.3276
Net Cash Flow:
$71.41M
1W Performance:
+15.54%
1M Performance:
+22.51%
6M Performance:
+52.38%
1Y Performance:
+36.43%
1-Day Range:
$10.12
$10.57
1-Week Range:
$8.915
$10.57
52-Week Range:
$5.81
$10.57
Bioventus Inc Stock (BVS) Company Profile
Name
Bioventus Inc
Sector
Industry
Phone
(919) 474-6700
Address
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
10.56 | 667.62M | 568.09M | 27.27M | 71.41M | 0.3276 |
ABT
Abbott Laboratories
|
101.56 | 175.59B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
341.24 | 132.47B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.10 | 113.14B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
64.61 | 94.85B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
78.20 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | CJS Securities | Market Outperform |
| Feb-09-26 | Initiated | Barrington Research | Outperform |
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-07-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-09-23 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-22-22 | Downgrade | Craig Hallum | Buy → Hold |
| Nov-09-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-09-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Mar-15-22 | Initiated | Craig Hallum | Buy |
| Nov-15-21 | Resumed | Morgan Stanley | Overweight |
| Nov-10-21 | Resumed | JP Morgan | Overweight |
| Jul-01-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-08-21 | Initiated | Canaccord Genuity | Buy |
| Mar-08-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Initiated | JP Morgan | Overweight |
| Mar-08-21 | Initiated | Morgan Stanley | Overweight |
View All
Bioventus Inc Stock (BVS) Latest News
Unaccepted RSU grant corrected for Bioventus (NASDAQ: BVS) director - Stock Titan
Bioventus (BVS) director amends filing on unaccepted 9,000 RSU grant - Stock Titan
Bioventus (BVS) CFO exercises 13,000 RSUs and withholds 5,648 shares for tax - Stock Titan
[Form 4] Bioventus Inc. Insider Trading Activity - Stock Titan
Bioventus (BVS) SVP gains 9,925 shares from RSU vesting, with tax withholding - Stock Titan
Bioventus (NASDAQ:BVS) Hits New 1-Year HighWhat's Next? - MarketBeat
(BVS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Are Investors Undervaluing Bioventus (BVS) Right Now? - Yahoo Finance
Aug Movers: Is Bioventus Inc stock showing strong momentumRecession Risk & AI Forecast for Swing Trade Picks - baoquankhu1.vn
JPMorgan Chase Trims Stake in Bioventus Inc. - National Today
JPMorgan Chase & Co. Cuts Stock Position in Bioventus Inc. $BVS - MarketBeat
Bone Growth Stimulator Market size to exceed $2.83 Billion - openPR.com
Momentum Shift: Is Bioventus Inc stock showing strong momentum2026 Market Outlook & AI Driven Stock Reports - baoquankhu1.vn
Stop Loss: Is Bioventus Inc exposed to currency risksEarnings Risk Report & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Bioventus Inc. (NASDAQ:BVS) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Investor Mood: Is Bioventus Inc exposed to currency risksWeekly Profit Recap & Safe Capital Growth Tips - baoquankhu1.vn
BVS.O Technical Analysis & Stock Price Forecast - Intellectia AI
BVS Should I Buy - Intellectia AI
BVS.O PE Ratio & Valuation, Is BVS.O Overvalued - Intellectia AI
BVS.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
BVS News & Events - Intellectia AI
(BVS) Risk Channels and Responsive Allocation - Stock Traders Daily
Surprises Report: Is Bioventus Inc in a bullish channel2026 Gainers & Daily Technical Stock Forecast Reports - baoquankhu1.vn
BVS PE Ratio & Valuation, Is BVS Overvalued - Intellectia AI
CJS Securities Initiates Coverage on Bioventus (NASDAQ:BVS) - Defense World
BVS Technical Analysis & ETF Price Forecast - Intellectia AI
Bioventus (BVS) CFO vests 18,625 RSUs with 8,091 shares withheld for taxes - Stock Titan
(BVS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Bioventus Inc.(NasdaqGS: BVS) added to S&P Healthcare Equipment Select Industry Index - marketscreener.com
BVS Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
Aug Wrap: Does Bioventus Inc offer margin of safetyEarnings Growth Summary & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Barrington Research initiates coverage of Bioventus (BVS) with outperform recommendation - MSN
Does Bioventus Inc have a competitive edge2026 Buyback Activity & Growth Focused Stock Pick Reports - baoquankhu1.vn
Bioventus (BVS) CFO receives major stock awards and exercises RSUs - Stock Titan
Bioventus (BVS) SVP granted RSUs, options and exercises prior awards - Stock Titan
Bioventus (BVS) SVP & General Counsel receives RSU, option grants and exercises awards - Stock Titan
Bioventus (BVS) CEO adds major RSU and option grants, exercises awards - Stock Titan
Travel Stocks: Is Bioventus Inc attractive for institutional investors2026 WrapUp & Community Shared Stock Ideas - baoquankhu1.vn
Bioventus : Corporate PresentationMarch 2026 - marketscreener.com
Divisadero Street Capital Management LP Sells 385,116 Shares of Bioventus Inc. $BVS - MarketBeat
Insider Sell: Michelle Mcmurry-heath Sells 12,000 Shares of Biov - GuruFocus
Bioventus (NASDAQ:BVS) Director Michelle Mcmurry-Heath Sells 12,000 Shares - MarketBeat
Bioventus (BVS) director logs open-market sale of 12,000 shares - Stock Titan
Bioventus Receives Consensus Buy Rating from Analysts - National Today
Bioventus Inc. (NASDAQ:BVS) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates - MSN
Bioventus stock delivers 63% return after Fair Value signal By Investing.com - Investing.com Australia
Bioventus stock delivers 63% return after Fair Value signal - Investing.com India
Liquidity Mapping Around (BVS) Price Events - Stock Traders Daily
Orthobiologics Market to Surpass USD 9 Billion by 2031 Amid Rising Osteoarthritis Cases and Advancements in Regenerative Therapies, Says Mordor Intelligence - GlobeNewswire Inc.
BVS (NASDAQ: BVS) files Form 144 for 12,000 Class A shares via Fidelity - Stock Titan
Bioventus Inc Stock (BVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bioventus Inc Stock (BVS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| CHURCH KATRINA J | SVP & Chief Compliance Officer |
Apr 10 '26 |
Option Exercise |
0.00 |
4,300 |
0 |
66,032 |
| D'Adamio Anthony | SVP & General Counsel |
Apr 10 '26 |
Option Exercise |
0.00 |
9,925 |
0 |
157,967 |
| Singleton Mark Leonard | SVP & CFO |
Mar 20 '26 |
Option Exercise |
0.00 |
18,625 |
0 |
178,072 |
| Singleton Mark Leonard | SVP & CFO |
Mar 13 '26 |
Option Exercise |
0.00 |
13,500 |
0 |
165,312 |
| CHURCH KATRINA J | SVP & Chief Compliance Officer |
Mar 13 '26 |
Option Exercise |
0.00 |
6,955 |
0 |
63,253 |
| D'Adamio Anthony | SVP & General Counsel |
Mar 13 '26 |
Option Exercise |
0.00 |
17,636 |
0 |
151,844 |
| Claypoole Robert E | President and CEO |
Mar 13 '26 |
Option Exercise |
0.00 |
33,500 |
0 |
150,497 |
| McMurry-Heath Michelle | Director |
Mar 11 '26 |
Sale |
8.79 |
12,000 |
105,439 |
44,997 |
2.40%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):